The purpose of this study is to find out the safest dose of these modified cells that can be given to patients and to see how well the treatment works. The study will look at how many patients experience serious side effects within 28 days after receiving the treatment, which will help determine the best dose to use in the next part of the study. The study will also measure how well the treatment works by checking if the cancer responds to the treatment and how long patients remain free from disease.

During the study, patients will first have their own immune cells collected. These cells will then be modified in a laboratory to target the cancer cells. Before receiving the modified cells back, patients may receive chemotherapy to prepare their body for the treatment. After the modified cells are given through an infusion into a vein, patients will be monitored closely for side effects and to see how well the treatment is working. The study will follow patients for up to 12 months to track their progress and see if the cancer comes back. This study is for children and young adults between 1 and 45 years of age who have tried other treatments that did not work or who cannot receive other standard treatments.

The purpose of this study is to evaluate how well these treatments work in patients whose lymphoma has returned or did not respond to initial treatment. The study is divided into different treatment groups, with some patients receiving new targeted therapies while others receive combinations of standard chemotherapy medications.

During the study, patients will receive their assigned treatment and have regular medical evaluations to check how well the treatment is working. The treatment period may last up to 24 months, depending on which medication group the patient is assigned to. Doctors will monitor patients’ response to treatment using imaging scans and other medical tests to assess if the cancer is responding to the therapy.

The purpose of the study is to find the best dose of Glofitamab when used alone and in combination with Obinutuzumab, and to understand how safe and effective these treatments are for patients with this type of lymphoma. Participants in the study will receive these medications through an infusion, which means the medicine is given directly into the bloodstream through a vein. The study will monitor how the body responds to the treatment, including any side effects and how well the cancer responds.

Throughout the study, doctors will carefully observe the participants to ensure their safety and to gather information on how the treatment affects the cancer. The study aims to provide valuable insights into the potential benefits and risks of using Glofitamab and Obinutuzumab for treating relapsed/refractory B-cell non-Hodgkin’s lymphoma, which could lead to new treatment options for patients in the future.

Participants in the study will receive the treatment over a period of several weeks. The study will monitor the response of the lymphoma to the treatment, as well as any side effects experienced by the participants. The goal is to determine the overall response rate, which refers to how many patients experience a reduction in the size of their tumors or other signs of improvement. The study will also look at other outcomes, such as progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse, and overall survival, which is the length of time from the start of treatment that patients are still alive.

Throughout the study, the safety and tolerability of the treatment will be closely monitored. This means that researchers will keep track of any adverse effects or serious adverse effects that participants may experience. The study aims to provide valuable information about the effectiveness and safety of this treatment combination for patients with aggressive lymphoma, potentially leading to improved treatment options in the future.

The medication being tested comes in the form of film-coated tablets that are taken by mouth. The purpose of this study is to determine how effective valemetostat tosylate is when used alone in treating these types of lymphoma. The treatment may continue for up to three years, depending on how well patients respond to the medication.

During the study, doctors will monitor how patients respond to the treatment by performing regular medical examinations and scans. They will specifically look at whether the cancer shrinks or disappears in response to the medication. The study will also track how long any positive responses to the treatment last and evaluate the safety of the medication.

The purpose of the study is to determine how safe MB-CART2019.1 is and how well it works in treating these cancers. The study will also use other medications, including fludarabine, cyclophosphamide, and tocilizumab, which are given to help prepare the body for the cell therapy or to manage side effects. Participants will receive these treatments through an intravenous infusion, which means the medicine is given directly into a vein.

During the study, participants will receive the treatment and be monitored closely to see how their cancer responds and to check for any side effects. The study will take place over several months, with regular check-ups to assess the effectiveness of the treatment and the health of the participants. The goal is to find out if this new approach can provide a better outcome for children and adolescents with these challenging types of cancer.

Participants in the study will receive Epcoritamab along with other medications, which may include Revlimid (containing lenalidomide), Decortin (containing prednisolone), Cyclophosphamide, Truxima (containing rituximab), IMBRUVICA (containing ibrutinib), Venetoclax (also known as ABT-199), Adriblastin (containing doxorubicin hydrochloride), Polivy (containing polatuzumab vedotin), and Golcadomide (also known as BMS-986369/CC-99282). Some participants may receive a placebo instead of one of these medications. The study will help determine the best dose of Epcoritamab to use in future research.

The study will take place over several years, with participants receiving treatment and being monitored for any side effects or changes in their condition. The researchers will look at how the cancer responds to the treatment, how long any positive effects last, and how long it takes for the cancer to progress or for participants to need another type of treatment. This information will help doctors understand how effective Epcoritamab is when used with other cancer treatments for people with B-cell Non-Hodgkin’s lymphoma.

Participants in the study will receive Epcoritamab through injections under the skin. The study will be conducted in phases, starting with a dose-escalation phase to determine the safest and most effective dose. After this, the study will expand to include more participants to further evaluate the treatment’s effectiveness. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Epcoritamab. The study will also explore whether adjusting the dose can reduce the risk of a side effect known as CRS (Cytokine Release Syndrome), which can cause symptoms like fever and fatigue.

In addition to Epcoritamab, the study may involve other medications such as Paracetamol (also known as acetaminophen), Dexamethasone, Betamethasone, Anakinra, Siltuximab, Diphenhydramine, and Tocilizumab. These medications are used to manage symptoms or side effects during the trial. The study aims to gather information over several years to understand the long-term effects and benefits of Epcoritamab for patients with B-cell lymphoma.

Participants in the study will receive either the new treatment or the standard treatment. The new treatment, MB-CART2019.1, is given as an infusion, which means it is administered directly into the bloodstream through a vein. The standard treatment, R-GemOx, also involves infusions of the three medications. The study will monitor participants over a period to see how well the treatments work and to check for any side effects.

The study aims to find out if MB-CART2019.1 is more effective than the standard treatment in helping patients with R-R DLBCL who are not eligible for high-dose chemotherapy and stem cell transplantation. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather information on the effectiveness of the treatments.

The purpose of the study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive a pre-treatment dose of Obinutuzumab before starting the combination therapy. The study will be conducted in different phases to determine the best dose and to observe how the body processes the medications. The study will also look at how well the treatment works in reducing the size of the tumors and controlling the disease.

Throughout the study, participants will be closely monitored for any side effects and how their bodies respond to the treatment. The study aims to find the most effective dose that can be safely given to patients. This research is important for developing new treatment options for people with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma and potentially improving their outcomes. The study is expected to continue until 2026, with the goal of gathering comprehensive data on the treatment’s safety and effectiveness.

The purpose of the study is to assess how well Axi-Cel works as a second-line therapy for patients who cannot undergo a procedure called autologous stem cell transplantation. This is a treatment option that uses a patient’s own stem cells to help recover from high-dose chemotherapy. The study will monitor the patients’ response to the treatment over a period of time, specifically looking at the complete metabolic response, which is a measure of how much the cancer has decreased or disappeared, at three months after receiving Axi-Cel.

Participants in the study will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will track the progress of the participants at various intervals to see how the treatment affects their cancer and overall health. The goal is to gather information on the effectiveness and safety of Axi-Cel in treating this type of lymphoma. The study is expected to continue until 2025, providing valuable insights into this promising treatment option.

Participants in the study will receive Mosunetuzumab either as a solution for injection under the skin or as a solution for infusion into a vein. The study will also explore how the body processes the medication, which is known as pharmacokinetics. Some participants will receive a combination of Mosunetuzumab and Atezolizumab, which is also given as a solution for infusion. The study will monitor the participants over time to assess how well the treatment works and to identify any side effects or adverse reactions.

The trial aims to determine the best dose and schedule for using Mosunetuzumab alone or with Atezolizumab. It will also compare the effectiveness of the treatment when given by different methods, such as injection versus infusion. The study is expected to continue until November 2025, and it will provide valuable information on the potential benefits and risks of these treatments for patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia.

The purpose of the study is to evaluate the effectiveness of MB-CART2019.1 in treating DLBCL. Participants will first receive a preparatory treatment to reduce the number of existing immune cells, known as a conditioning lymphodepletion regimen, before receiving the MB-CART2019.1 infusion. The study will monitor the participants’ response to the treatment over time, assessing how well the cancer responds and any changes in the participants’ health. Some participants may receive a placebo as part of the study to compare the effects of the treatment.

Throughout the study, participants will undergo regular health assessments, including imaging tests like MRI to track the progress of the treatment. The study aims to determine the overall response rate, which includes both partial and complete responses to the treatment. Additionally, the study will evaluate the duration of the response, progression-free survival, and overall survival, as well as monitor any side effects or adverse events that may occur. The study is expected to continue until 2027, with recruitment starting in 2024.

The purpose of this study is to evaluate the long-term safety of these therapies. Patients who have received these treatments will be monitored over time to check for any late-onset side effects or serious health events. This includes looking for any new or returning cancers, serious infections, or other significant health issues. The study will also track the presence of certain cells in the blood, such as B and T lymphocytes, and other health indicators like height and weight in children. The presence of any remaining modified cells from the therapy will also be checked.

Participants in this study will have regular follow-up visits where their health will be assessed. This includes checking for any signs of the cancer returning or progressing and monitoring overall survival rates. The study aims to ensure that the treatments are safe in the long term and to gather important information that can help improve future therapies. The study is expected to continue until the end of 2040, providing valuable insights into the long-term effects of these innovative treatments.

The purpose of the study is to evaluate the safety and effectiveness of UCART20x22 in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. The study is divided into two parts: the first part aims to find the best dose of the treatment, while the second part will further test the treatment’s safety and confirm the best dose. Participants will receive the treatment through an intravenous infusion, which means it will be administered directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and the treatment’s ability to control the cancer. The study will also involve other medications, such as Fludarabine and Cyclophosphamide, which are commonly used in cancer treatment. These medications help prepare the body to receive the cell therapy. The trial will continue for several years to gather comprehensive data on the treatment’s long-term effects and benefits.

The study will be conducted in different parts. Initially, the safety and tolerability of MEN1703 alone and in combination with Glofitamab will be assessed. This means researchers will monitor how well patients tolerate the medications and any side effects that may occur. Following this, the study will focus on the ability of these treatments to fight the lymphoma, which is a type of cancer that affects the lymphatic system, a part of the body’s immune system. The study will involve regular monitoring and assessments to track the progress and response of the cancer to the treatments.

Participants in the study will receive either the combination of MEN1703 and Glofitamab or MEN1703 alone. Some participants may also receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study aims to provide valuable information on the potential benefits and risks of these treatments for patients with this challenging form of lymphoma. The trial is expected to continue until the end of 2026, with recruitment starting in late 2024.